Boehringer Ingelheim’s Social Engagement Fund has added four healthcare companies to its portfolio, extending a €50 million impact-investment vehicle that the German pharmaceutical group now projects will help exceed its 2021 commitment to improve the lives of 50 million people by 2030.
The four additions — Viya Health, BIMA Milvik, Chefaa, and Penda Health — are the fund’s latest impact-first debt investments, bringing its total portfolio to 27 social start-ups, of which 24 operate in Africa and three in Latin America. Boehringer said 80 per cent of the €50 million fund has been committed, with another 38 companies having received support to prepare for potential funding.
The announcement coincided with the company’s “Making More Health Together” convention in Ingelheim, which drew more than 400 health entrepreneurs, investors, and healthcare-system partners. Boehringer also disclosed that its broader investments in sustainability-related programmes and health partnerships are projected to reach €500 million by the end of 2026, of which more than €125 million has been directed toward combating emerging infectious diseases, including antimicrobial resistance.
A fund designed to be repaid
Established in 2021, the Social Engagement Fund was structured to address what Boehringer describes as a critical financing gap for social start-ups seeking to scale healthcare solutions in low- and middle-income countries. Unlike traditional philanthropic grants, the fund uses impact-first debt instruments — loans designed to prioritise measurable health outcomes over maximum financial returns. Boehringer expects approximately 50 to 75 per cent of the financing provided to be repaid from 2032 onward, with the intention of reinvesting those returns into a new generation of health entrepreneurs, developing the fund into a more self-sustaining impact-financing platform.
“As a family-owned company, we think in generations, not in quarters,” said Hubertus von Baumbach, Chairman of the Boehringer Ingelheim Shareholders’ Committee, in a statement. “Many promising ideas begin with the potential to transform lives — but their impact remains limited unless they can scale. Scaling requires more than capital; it depends on strong networks, the right partners and access to expertise”.
The fund’s investment portfolio spans primary care, health insurance, diagnostics, telehealth, mobile clinics, and last-mile medicine delivery — a deliberate diversification strategy to build complementary capabilities across the healthcare value chain rather than concentrating on a single segment.
Viya Health: bridging the women’s health gap
Among the four new recipients, Viya Health addresses a persistent disparity in global health: women in low- and middle-income countries spend more years in poor health than men and face significant gaps in access to care across family planning, sexual health, and menopause management. Viya offers health products and services spanning family planning, menopause, and metabolic health through local partnerships and digital channels, reaching 43 million people across 19 countries by the end of 2025.
The investment aligns with a broader push to close a funding gap that the World Economic Forum estimates leaves women’s health receiving only 6 per cent of private healthcare investment — less than one in ten dollars — despite women representing nearly half the global population. Women lose 25 per cent more of their lives to poor health than men, according to a joint report by the WEF and Boston Consulting Group published in January 2026.
“Women tend to spend more years in poor health than men. Addressing this disparity could add up to 1 trillion USD to the global economy annually by 2040,” said Marcie Cook, President of Viya Health. “With support from Boehringer, Viya Health is expanding from family planning into a holistic women’s health platform, reaching more than 100 million women.”
BIMA Milvik: insurance as a gateway to care
BIMA Milvik takes a different approach, integrating telemedicine, diagnostics, and insurance into a single subscription product called B-Care, priced for low- and middle-income households across six markets in Africa and Asia. The company, headquartered in Singapore, operates a network of 1,200 field agents and has served over 41 million people through direct-to-consumer products and telecommunications partnerships as of December 2025.
BIMA claims that B-Care offers “up to five times better value compared to traditional insurance,” combining cashless inpatient and outpatient coverage with 24-hour doctor consultations. The company is also investing in artificial intelligence and data-driven tools to streamline claims processing and personalise care.
“At BIMA, we believe quality healthcare and financial protection should not be a privilege,” said Gustaf Agartson, Founder and CEO. “The funding from Boehringer Ingelheim’s Social Engagement Fund helps us extend that reach further across Africa and Asia.”
Chefaa: digitising Egypt’s pharmacy supply chain
In Egypt, Chefaa operates a digital health and e-pharmacy platform connecting patients with licensed pharmacies for medicines and health products. The company offers GPS-enabled delivery, pharmacist consultations, medication reminders, and health management tools. By the end of 2025, Chefaa had reached more than 2 million patients through a network of over 1,000 pharmacies and more than 1 million app downloads.
High out-of-pocket healthcare costs and fragmented pharmacy access continue to limit medicine access in Egypt, where private household spending accounts for the majority of total health expenditure. Chefaa’s model aims to reduce friction in the last mile between pharmacies and patients.
“For too many Egyptians, getting the right medicine on time still comes down to what they can afford and how far they have to travel,” said Dr. Rasha Rady, Co-Founder and Co-CEO. “Boehringer Ingelheim’s backing lets us reach more underserved communities.”
Chefaa has raised approximately $18.3 million across multiple funding rounds, according to PitchBook data, making it one of the more mature ventures in the Social Engagement Fund’s portfolio.
Penda Health: affordable outpatient care in Kenya
Penda Health operates 20 outpatient medical centres across Nairobi, complemented by 24/7 telemedicine services. The model combines consultations, diagnostics, pharmacy, and other services, with AI-supported clinical decision tools to improve consistency of care. Penda had served more than 600,000 patients across its centres by the end of 2025, supplemented by over 70,000 monthly telemedicine engagements.
The need is acute: in Kenya, out-of-pocket payments account for at least a quarter of total health spending, with the poorest households spending close to a third of their income on healthcare. Penda’s services are priced up to 83 per cent cheaper than those offered by other high-quality private healthcare providers, according to development financier Finnfund, which invested $2.5 million in the company in 2018.
“At Penda, we believe every family deserves care they can trust and afford,” said Stephanie Koczela, Co-Founder and CEO. “This partnership helps us open more medical centres, strengthen the technology behind our care, and reach more patients.”
Beyond capital: skills-based support
Boehringer said the fund will provide skills-based support to the four innovators, including strengthening governance, supporting market expansion, and building connections with relevant partners. The company also plans to connect the fund with wider health initiatives, including CRM Patient Africa and the Angels Initiative, giving supported entrepreneurs access to clinical expertise, distribution networks, and policymakers.
The Social Engagement Fund sits within a broader trend of pharmaceutical companies deploying impact-investment vehicles to address healthcare access gaps that pure commercial models have struggled to bridge. The Transform Health Fund, a $109.9 million vehicle focused on growth-stage healthcare companies in Africa, was awarded a Platinum rating by BlueMark in 2026, while the Multiply Health Fund, a blended-finance vehicle launched in March 2026, aims to unlock catalytic and commercial capital for high-impact healthcare businesses across the continent.
Whether the Social Engagement Fund’s impact-first debt model can deliver both measurable health outcomes and eventual financial returns will be tested over the coming decade. For now, the fund’s expansion reflects a strategic bet that the most durable solutions to healthcare access in underserved markets will come from commercially viable enterprises — not from aid alone.
Boehringer Ingelheim reported group net sales of €27.8 billion in 2025, a 7.3 per cent increase, with research and development spending reaching €6.4 billion, or 22.9 per cent of net sales. The company employs approximately 54,300 people and serves over 130 markets.
“We are proud to keep up the momentum and support these highly impactful social businesses,” said Ilka Wicke, Global Head of Social Engagement Fund at Boehringer Ingelheim. “Together, we can strongly scale up access to critical healthcare services and products for those patients that need it most.”